SCHEMBL26081049

SCHEMBL26081049

N#Cc1ccc(CC2(O)CCCCC2)c(F)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RORC P51449 1/20 0.38
ESR1 P03372 1/20 0.38
ESR2 Q92731 1/20 0.38
FFAR1 O14842 3/20 0.38
FFAR4 Q5NUL3 3/20 0.38
P2RX7 Q99572 2/20 0.37
PGR P06401 2/20 0.37
USP2 O75604 1/20 0.35
TSHR P16473 1/20 0.35
TRPA1 O75762 2/20 0.34
HTR2A P28223 2/20 0.34
DRD2 P14416 1/20 0.34
HTR2C P28335 1/20 0.34
KCNH2 Q12809 1/20 0.34
NR3C1 P04150 1/20 0.34
NR3C2 P08235 1/20 0.34
TRPV4 Q9HBA0 1/20 0.34
CYP11B1 P15538 1/20 0.33
CYP11B2 P19099 1/20 0.33
USP30 Q70CQ3 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26081047 0.84 RORC (0.39) RORCESR1ESR2FFAR1FFAR4
SCHEMBL26081051 0.80 USP2 (0.34) P2RX7PGRUSP2TSHRTRPA1
SCHEMBL26081071 0.80 KDM4E (0.47) USP2TSHRTRPA1HTR2A
SCHEMBL26081050 0.77 CYP3A4 (0.43) P2RX7USP2TSHR
SCHEMBL10192218 0.77 FPR2 (0.48) P2RX7USP2TSHRHTR2C
SCHEMBL10192232 0.77 FPR2 (0.48) P2RX7USP2TSHRHTR2C
SCHEMBL377037 0.74 KDM4E (0.52) HTR2ADRD2HTR2CKCNH2AR
SCHEMBL24484644 0.73 P2RX7 (0.37) RORCESR1ESR2FFAR1FFAR4
SCHEMBL10191864 0.73 ALDH1A1 (0.44) USP2TSHR
SCHEMBL10192225 0.73 ALDH1A1 (0.44) USP2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230312522-A1 CYP46A1 INHIBITORS AND METHODS OF USE THEREOF SAGE THERAPEUTICS, INC. 2023-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230312522-A1 CYP46A1 INHIBITORS AND METHODS OF USE THEREOF CYP46A1, CYP26A1, CYP4A22 RORC 317/4885ESR1 2574/4885ESR2 1755/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.